NasdaqGS:GILDBiotechs
Is Gilead’s Global Lenacapavir Access Deal Reframing the Investment Case for GILD?
Recently, Gilead Sciences announced a multi-year partnership with the U.S. State Department and PEPFAR to deliver its twice-yearly HIV prevention therapy, lenacapavir, to up to two million people in PEPFAR- and Global Fund-supported countries, alongside new manufacturing and product expansion efforts.
This initiative not only extends the global reach of Gilead’s innovative HIV therapy but also highlights the company’s recognized leadership in HIV philanthropy and advances in biopharma...